文献速递免疫规划传染病防控与疫情报告

缺NS1减毒活H5N1流感疫苗的安全性与免疫原性

Safety and immunogenicity of a replication-deficient H5N1 influenza virus vaccine lacking NS1.
PubMed 文献 · Vaccine · 2019-05-30

该研究为双盲、安慰剂对照的1期临床试验,健康成人按2:1随机接受两剂delNS1-H5N1疫苗(6.8或7.5 log10 TCID50/人)或安慰剂。鼻内接种安全且耐受良好,较低剂量即可诱导显著特异性血清抗体,7.5 log10 TCID50组单剂后75%发生血清转化。

要点

  • 鼻内接种缺NS1减毒活H5N1疫苗安全且耐受良好。
  • 6.8 log10 TCID50/人剂量即可诱导显著疫苗特异性血清抗体。
  • 7.5 log10 TCID50/人单剂后75%受试者发生血清转化。

核心结论

  • 缺NS1减毒活H5N1疫苗鼻内接种安全,单剂即可诱导显著疫苗特异性抗体,可能满足大流行时有效疫苗的需求。

研究设计与样本

  • 双盲、安慰剂对照的1期研究,健康成人按2:1随机接受两剂delNS1-H5N1疫苗(6.8或7.5 log10 TCID50/人)或安慰剂。

主要发现

  • 最常见不良事件为轻度流感样症状,如体温升高(>37.0 °C)、咽红、鼻炎和咽部刺激,均报告于首剂免疫后7天内。
  • 6.8 log10 TCID50/人剂量即可诱导显著疫苗特异性血清抗体滴度。
  • 7.5 log10 TCID50/人单剂后75%受试者发生血清转化。
  • 第二剂后出现血清抗体应答者中41.7%观察到疫苗特异性局部IgA应答。

临床怎么用

  • 提示缺NS1减毒活H5N1疫苗可作为大流行情景下需单剂诱导免疫应答的候选策略。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Traditional inactivated influenza vaccines are the type of vaccines that were most frequently developed for immunization against the highly pathogenic avian H5N1 influenza virus. However, clinical trials with inactivated influenza vaccines for H5N1 indicated that high doses and at least two immunizations are required for an effective immune response (Nicholson et al., 2001; Treanor, Campbell et al., 2006; Treanor, Schiff et al., 2006; Ehrlich et al., 2008). We investigated the safety and immunogenicity of a live attenuated H5N1 vaccine (delNS1-H5N1) lacking the interferon antagonist nonstructural protein 1 (NS1). METHODS: We conducted a double-blind, placebo-controlled, phase 1 study in healthy adult participants who were randomly assigned at a 2:1 ratio to receive two immunizations of delNS1-H5N1 vaccine at 6.8 log10 50% tissue culture infectious doses (TCID50)/subject or 7.5 log10 TCID50/subject, or placebo. RESULTS: Intranasal vaccination with the live attenuated delNS1-H5N1 vaccine was safe and well tolerated. The most common adverse events identified were symptoms associated with mild influenza infections, such as increased body temperature (>37.0 °C), pharyngeal erythema, rhinitis and throat irritation, and were reported within 7 days after the first immunization. delNS1-H5N1 was able to induce significant vaccine-specific serum antibody titers even at the lower dose level of 6.8 log10 TCID50/subject. Seroconversion occurred in 75% of study participants after only one immunization with 7.5 log10 TCID50/subject. Vaccine-specific local IgA responses were observed in 41.7% of individuals that showed serum antibody responses after 2nd immunization. CONCLUSIONS: We show that vaccination with a live attenuated H5N1 influenza vaccine lacking NS1 is safe and induces significant levels of vaccine-specific antibodies even after one immunization. The safety and immunogenicity data indicate that delNS1-H5N1 has the potential to fulfil the unmet need for an effective influenza vaccine in pandemic situations. (ClinicalTrials.gov identifier NCT03745274).

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Nicolodi C, Groiss F, Kiselev O, et al. Safety and immunogenicity of a replication-deficient H5N1 influenza virus vaccine lacking NS1. Vaccine. 2019. PMID: 31155415. doi:10.1016/j.vaccine.2019.05.013

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。